



## Curriculum Vitae

Personal information **Maria Teresa Aldamiz Echevarria Lois**

### Work experience

---

1. Employer: HIV/Infectious Diseases Ward in Gregorio Marañón Hospital in Madrid
  - Start date: 2010
  - End date: ongoing
  - Position: Clinical researcher and HIV physician and infectious disease specialist
  - Activities:

Teresa Aldámiz-Echevarría Lois is an internal medicine physician with extensive experience working at the Gregorio Marañón Hospital, where she began her residency in 2005 and later continued as an attending physician from 2010 to the present. Throughout this time, she has been active in all areas of internal medicine, including inpatient care, outpatient clinics, day hospital, on-call duties, and emergency services. She has specialized in Infectious Diseases, with a particular interest in HIV infection. In this field, she has also developed extensive research activity, resulting in more than 100 publications indexed in PubMed.

She leads several research projects, including a Carlos III FIS project for which she is the principal investigator, focused on the study of the epidemiology and impact of HHV-8 in people living with HIV. She also collaborates on other FIS projects and directs additional projects supported through other grant calls.

- Country: Spain

### Education and training

---

1. Subject: Universidad de Santiago de Compostela, June 2004
  - Start date: 1st October 1998
  - End date: 30th June 2004
  - Qualification: Degree in Medicine and Surgery
  - Organisation: Universidad de Santiago de Compostela
  - Country: Spain
2. Subject:
  - Start date: 14th September 2003
  - End date: 30th June 2004
  - Qualification: ERASMUS (2003\_2004) Université Libre de Bruxelles
  - Organisation: Université Libre de Bruxelles
  - Country: Belgium
3. Subject:
  - Start date: 2007
  - End date: 2011
  - Qualification: PhD. Doctoral thesis\_Cum laude: "Estudio comparativo entre interferón pegilado alfa 2a con ribavirina e interferón pegilado alfa 2b con ribavirina para el tratamiento de la hepatitis crónica C en pacientes infectados por el virus de inmunodeficiencia humana".
  - Organisation: Universidad Compluense de Madrid
  - Country: Spain
4. Subject: Universidad Autónoma de Barcelona. 2012\_2014
  - Start date: 2012
  - End date: 2014
  - Qualification: Diplomatura en Diseño y Estadística en Ciencias de la Salud (Diploma in Statistics)
  - Organisation: Universidad Autónoma de Barcelona
  - Country: Spain
5. Subject:
  - Start date: 2011
  - End date: 2015
  - Qualification: Master en Medicina Tropical. Universidad Autónoma de Madrid
  - Organisation: Universidad Autónoma de Madrid
  - Country: Spain
6. Subject:
  - Start date: 2014
  - End date: 2015
  - Qualification: Master on HIV Infection (Master sobre infección por el Virus de la Inmunodeficiencia Humana).
  - Organisation: Universidad Rey Juan Carlos
  - Country: Madrid
7. Subject:
  - Start date: 2014
  - End date: 2015
  - Qualification: Title on HIV as chronic infection disease. Título de experto Abordaje del VIH como enfermedad crónica.
  - Organisation: Universidad de Alcalá de Henares.
  - Country: Spain

8. Subject:

- Start date: 2017
- End date: 2018
- Qualification: Expert on clinical research (Título de experto en investigación clínica).
- Organisation: Universidad Internacional Menéndez Pelayo
- Country: Spain

9. Subject:

- Start date: 2017
- End date: 2019
- Qualification: Master in infection control: Infections related to health care (Master en control de la infección: Infecciones relacionadas con la asistencia sanitaria).
- Organisation: Universidad Autónoma de Barcelona
- Country: Spai

## Additional information

### Publications

- Aldámiz-Echevarria T, Fanciulli C, Lopez M, Perez L, et al. Direct collaboration between hospitals and NGOs, an essential tool to reinforce linkage to care in people living with HIV. *Sci Rep.* 2025 Jan 28;15(1):3583. doi: 10.1038/s41598-025-86540-8. PMID: 39875449; PMCID: PMC11775109.
- Berenguer, Juan; Aldamiz-Echevarria, Teresa; Hontanon, Victor; et al; Gonzalez-Garcia, Juan. 2024. Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfecting patients with advanced Fibrosis/Cirrhosis. *HEPATOLOGY. LIPPINCOTT WILLIAMS & WILKINS.* ISSN 0270-9139, ISSN 1527-3350.
- Tarancon-Diez, Laura; Carrasco, Itziar; Ory, Santiago Jimenez de; et al; Angeles Munoz-Fernandez, M.2023. Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfecting youths with sustained viral response after direct-acting antivirals therapy. *BIOMEDICINE & PHARMACOTHERAPY. ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER.* 162. ISSN 0753-3322, ISSN 1950-6007.
- Tejerina, Francisco; Palomino, Rosalia; Catalan, Pilar; et al; Garcia de Viedma, Dario. 2023. Longitudinal Whole-genome Sequence Characterization of a Persistent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron BA.5 Infection in an Immunocompromised Patient Successfully Treated With Sotrovimab 1000 mg. *CLINICAL INFECTIOUS DISEASES.* ISSN 1537-6591.
- Joao Baptista, Maria; Tapia, Gustavo; Munoz-Marmol, Ana-Maria; et al; Navarro, Jose-Tomas. 2022. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. *HISTOPATHOLOGY. WILEY.* 81-6, pp.826-840. ISSN1365-2559.
- Veintimilla, Cristina; Catalan, Pilar; Alonso, Roberto; et al; Munoz, Patricia. 2022. The relevance of multiple clinical specimens in the diagnosis of monkeypox virus, Spain, June. *EUROSURVEILLANCE. EUR CENTRE DIS PREVENTION & CONTROL.* 27-33. ISSN 1025-496X.
- Tejerina, Francisco; Catalan, Pilar; Rodriguez-Grande, Cristina; et al; Gregorio Maranon Microbiol ID COVI. 2022. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. *BMC INFECTIOUS DISEASES. BMC.* 22-1. ISSN 1471-2334.
- Alvarez, Hortensia; Rava, Marta; Martinez, Cristina; et al; CoRIS Study Group. 2022. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort. *HIV medicine.* ISSN 1468-1293.
- Gonzalez Guembe, Maria; Tisner Pensado, Yago; Tejerina Picado, Francisco; et al; Gregorio Maranon Microbiology-ID. 2022. SARS-CoV-2 Infection in People Living with HIV: Experience from a Tertiary Hospital in Madrid. *AIDS RESEARCH AND HUMAN RETROVIRUSES. MARY ANN LIEBERT, INC.* 38-5, pp.394-398. ISSN 0889-2229.
- Different Within-Host Viral Evolution Dynamics in Severely Immunosuppressed Cases with Persistent SARS-CoV-2. Pérez\_Lago L, Aldámiz\_Echevarría T, García\_Martínez R, Pérez\_Latorre L, Herranz M, Sola\_Campoy PJ, Suárez\_González J, Martínez\_Laperche C, Comas I, González\_Candelas F, Catalán P, Muñoz P, García de Viedma D, On Behalf Of Gregorio Marañón Microbiology\_Id Covid Study Group. *Biomedicines.* 2021 Jul 13;9(7):808.
- European mitochondrial haplogroups predict liver-related outcomes in patients coinfecting with HIV and HCV: a retrospective study. Teresa Aldámiz\_Echevarría, Salvador Resino, José M. Bellón, María A. Jiménez\_Sousa, Pilar Miralles, Luz M. Medrano, Ana Carrero, Cristina Díez, Leire Pérez\_Latorre, Chiara Fanciulli, Pilar García\_Broncano, Juan Berenguer. *J Transl Med.* 2019; 17: 244.
- Delayed haemolysis secondary to treatment of severe malaria with intravenous artesunate: Report on the experience of a referral centre for tropical infections in Spain. Aldámiz\_Echevarría T, López\_Polín A, Norman FF, Monge\_Maillo B, López\_Vélez R, Pérez\_Molina JA. *Travel Medicine and Infectious Diseases* 2016 Nov 3. En prensa.
- Soluble Adhesion Molecules in Patients Coinfecting with HIV and HCV: A Predictor of Outcome. Aldámiz\_Echevarría T, Berenguer J, Miralles P, Jiménez\_Sousa MA, Carrero A, Pineda\_Tenor D, Díez C, Tejerina F, Pérez\_Latorre L, Bellón JM, Resino S. *PLoS One.* 2016 Feb 5;11(2):e0148537.
- Association of baseline CD4+ cell count and HIV\_RNA on sustained virologic response to interferon\_ribavirin in HIV/HCV coinfecting patients. Teresa Aldámiz\_Echevarría, Juan González\_García, Miguel A Von Wichmann, Manel Crespo, José López\_Aldeguer, Carmen Quereda, María J Téllez, María J Galindo, José Sanz, Ignacio Santos, Josep M Guardiola, José M Bellón, Marisa Montes, Juan Berenguer. *Annals of Hepatology.* 2015. Jul\_Aug; 14(4): 464\_9.
- Coinfection: Comparison of Hepatic Venous Pressure Gradient and Transient Elastography. Pérez\_Latorre L, Sánchez\_Conde M, Rincón D, Miralles P, Aldámiz\_Echevarría T, Carrero A, Tejerina F, Díez C, Bellón JM, Bañares R, Berenguer J. *Clin Infect Dis.* 2014 Mar;58(5):713\_8. • Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfecting patients. Guzmán\_Fulgencio M, García\_Álvarez M, Berenguer J, Jiménez\_Sousa MÁ, Cosín J, Pineda\_Tenor D, Carrero A, Aldámiz\_T, Alvarez E, López JC, Resino S. *J Infect.* 2014 Feb;68(2):176\_84.
- Prediction of hepatic fibrosis in patients coinfecting with human immunodeficiency virus and hepatitis C virus based on genetic markers. Fernández\_Rodríguez A, Berenguer J, Jiménez\_Sousa MA, Guzmán\_Fulgencio M, Micheloud D, Miralles P, López JC, Bellón JM, Aldamiz\_Echevarria T, García\_Broncano P, Carrero A, Alvarez E, Resino S. *J Acquir Immune Defic Syndr* 2013 Dec;64(5):434\_42.
- European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy. Guzmán\_Fulgencio M, Berenguer J, Micheloud D, Fernández\_Rodríguez A, García\_Álvarez M, Jiménez\_Sousa MA, Bellón JM, Campos Y, Cosín J, Aldámiz\_Echevarría T, Catalán P, López JC, Resino S. *J Antimicrob Chemother* 2013 Oct 7;68(10):2349\_57.
- Bacterial DNA translocation and liver disease severity among HIV-infected patients with chronic hepatitis C. García\_Álvarez M, Berenguer J, Guzmán\_Fulgencio M, Alvarez E, Cosín J, Micheloud D, Jimenez\_Sousa MA, Fernández\_Rodríguez A, Aldámiz\_Echevarría T, Carrero A, Miralles P, Resino S. *JAIDS.* 2012. 61(5):552\_6.

Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Berenguer and GESIDA 36/03 and 50/06 Study Groups. J Antimicrob Chemother 2011; 66(12):2843\_9.

Sustained virological response to interferon\_α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. M Guzmán\_Fulgencio, J Berenguer, I Fernández de Castro, D Micheloud, JC López, J Cosin, P Miralles, R Lorente, T Aldámiz\_Echevarría, MA Muñoz Fernández, S Resino. JAC 2011; 66: 645\_649.

Kraef, Christian; Bentzon, Adrian; Pantelev, Alexander; et al; TB HIV Study Grp. 2021. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study. BMC INFECTIOUS DISEASES. BMC. 21-1. ISSN 1471-2334.

## Projects

### Competitive Research Projects

#### 1.- Funded by national and regional administrations

**PI 23/01706.** Project title: "HHV-8 and HIV: Seroprevalence of HHV-8 in the HIV-positive population in Spain. HHV-8 PCR, phylogenetic study, and inflammatory markers in co-infected individuals. Impact of antineoplastic therapies."

Principal Investigator: Teresa Aldámiz-Echevarría Lois  
Start date: January 2024

**PI21/00444.** Project title: "Tolerability and safety of three short rifamycin-based regimens for tuberculosis prevention in renal transplant recipients: a randomized clinical trial."

Principal Investigator: Miguel Satin Cerezales  
Collaborating Researcher: Teresa Aldámiz-Echevarría Lois  
Start date: November 2024 (extended)

**PI 17/00657.** Project title: "Long-term morbidity and mortality after HCV eradication in HIV/HCV co-infected patients with advanced liver fibrosis/cirrhosis."

Principal Investigator: Juan Berenguer Berenguer  
Collaborating Researcher: Teresa Aldámiz-Echevarría Lois  
Start date: January 2018

#### JR17/00018: Juan Rodés Contract

Principal Investigator: Teresa Aldámiz-Echevarría Lois  
Start date: February 2018

#### 2.- Grants

**Collaborating Researcher** in the *Thematic Networks for Cooperative Health Research*, project titled "Spanish HIV Research Network (RIS)", file number RD16/0025/0017. Duration: 5 years. Participation certified from Start Date: 01/01/2017 to End Date: 31/12/2022. Host institution: Gregorio Marañón Hospital. Principal Investigator: Juan Berenguer Berenguer.

**Gilead Grants.** Project: "Achieving the 95 Targets". Grant ID Number: 14855. Year: 2022.

#### 3.- Clinical Trials:

- GS-US-334-0124.** A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults. 1/04/2013 to 12/09/2014. Promotor: Gilead Sciences.
- GS-US-292-0104.** Phase III, randomized, double-blinded study, Estudio de Fase 3. Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive. July 2013 to December 2016. Promotor: Gilead Sciences.
- GSK1265744 y TMC278:** Phade IIB estudio de fase IIB. Effectiveness, safety/tolerability of intramuscular long-acting treatment with GSK1265744 y TMC278". Promotor: Glaxosmithkline.
- Vie-Real:** Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Promotor: Abbvie.
- VX 950-115. Vertex.** Open label, Randomized, phase III to evaluate efficacy and safety of telaprevir in combination with peginterferón α2a (Pegasys®) and ribavirine (Copegus®) in coinfecting subject with hepatitis C and HIV. Promotor: Vertex Pharmaceuticals Incorporated. June 2012 to 2-04-2014.
- BOC-VIH,** y EudraCT 2012-003984-23. Open label, phase III to evaluate efficacy and safety of c boceprevir in coinfecting subject with hepatitis C and HIV who failed peginterferon. 10/09/2013 to 01/09/2015. Promotor: Merck Sharp & Dohme Corp.
- AI 444-043:** phase III open study to evaluate safety and effectiveness of triple therapy with bms-790052 plus interferón alfa-2a and ribavirin in HIV-positive Patients with Hepatitis C. February 2012 to 22/07/2014. Promotor: Bristol-Myers Squibb.
- Estudio AI 444-046:** Follow up for patients treated with daclatasvir and asunaprevir for participants in A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. 03/10/2013 to may 2017. Promotor: Bristol-Myers Squibb.
- MK-1439-018,** clinical trial phase III. Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). 04/2015-26/01/2021. Promotor: Merck Sharp & Dohme Corp.
- TMC1141IFD3013:** Phase III multicentric randomized, open study to compare in efficacy and safety D/C/F/TAF once per day in STR vs a PI regimen for undetectable viral load HIV patients. Mayo 2015 a 13/02/2019. Promotor: Janssen.
- L-TAP2.** Phase III. Lipid Treatment Assessment Project 2. Lipid goals among patients with diabetes or metabolic syndrome. Sept-2006 to April de 2007. Promotor: Pfizer.
- MK-0859-019.** Phase III: Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease. May 2008 to December 2017. Promotor: Merck Sharp & Dohme Corp.
- HIPRA-HH-2:** A Phase IIB, double-blind, randomized, active controlled, multi-centre, noninferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2, in adults fully vaccinated against COVID-19. promotor HIPRA SCIENTIFIC, S.L.U. 71 months
- HIPRA-HH-5:** A phase III, open, label trial, single arm, multi-centr trial to assess the safety
- a. and immunogenicity of a booster vaccination with a recombinant proteiB RBD fusion
- b. heterodimer candidate (PHH-1V) against SARS-CoV-2 in adults vaccinated against COVID-19. Promotor HIPRA SCIENTIFIC, S.L.U. 56 months.
- HIPRA-HH-10:** A phase IIB, double-blind, randomized, active controlled, multi-centre, non-inferiority trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-COV.2, in adults fully vaccinated with adenovirus vaccine against COVID-19. Promotor HIPRA SCIENTIFIC, S.L.U. 40 months.
- 219700-Viiv-DTG/3TC:** phase IIIb, multicentric, no-randomized, parallel group, open-label, hybrid type I evaluating the efficacy, safety, implementation effectiveness, and patient-reported outcomes of oral

dolutegravir/lamivudine once daily as first-line treatment, followed by a change from an optional switch chosen by the participant to injectable treatment with cabotegravir plus long-acting rilpivirine administered intramuscularly every two months for maintenance of virologic suppression in untreated adults with HIV-1 prior antiretroviral. Promotor VIIV HEALTHCARE UK LIMITED. 17 months.

18. **MK-8591A-051**: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). Promotor MERCK SHARP & DOHME LLC. 32 months
19. **MK-8591A-053**: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). Promotor MERCK SHARP & DOHME LLC. 41 months
20. **MK-8591A-054**: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). Promotor MERCK SHARP & DOHME LLC. 36 months.
21. **212483 GSK3640254 Viiv**: Phase IIb, randomized, double-blind, parallel-group study to evaluate the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1-infected adults without prior treatment. Promotor VIIV HEALTHCARE UK LIMITED. 28 months.
22. **MK-8591A-020**: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). Promotor MERCK SHARP & DOHME LLC. . Mayo 2021. Promotor: Merck Sharp & Dohme Corp.
23. **MK-8591A-017**: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). Promotor MERCK SHARP & DOHME LLC. 30 months
24. **MK-8591A-018**: Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1). Promotor MERCK SHARP & DOHME LLC. 30 months
25. **WA42380**. "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Severe COVID-19 Pneumonia-COVACTA". A 25/03/2020 a 30/06/2021. Promotor Roche.
26. **VOLITION**-current. Promotor: VIIV HEALTHCARE UK LIMITED
27. **MK8591A-093**-current. Promotor: Merck Sharp & Dohme Corp.
28. **CROWN**-current. Promotor: VIIV HEALTHCARE UK LIMITED

## Memberships

Member of Gesida (Spanish Group for the study of HIV) and SEISIDA (Spanish Interdisciplinary AIDS Society).

Contributing author of the national Gesida guidelines for the management and treatment of patients with HIV infection (the 2025 and 2023 antiretroviral treatment guidelines, and the 2021 clinical practice guideline on human herpesvirus 8 infection in people with HIV).

Participates in scientific committees of both Gesida and the Spanish Society of Infectious Diseases.

Secretary of the Carlos III CoRIS Cohort (Cohort of the HIV/AIDS Research Network), established in 2004 for HIV research.

Collaborator with study groups on HIV and HCV (Madrid CoRe), Tuberculosis and HIV (EuroCoord), HIV-2 and HTLV (Spanish HIV-2/HTLV Study Group), and GELTAMO (Spanish Group on Lymphomas and Bone Marrow Transplantation).

## Other Relevant Information

Associate Professor of Infectious Diseases at the Complutense University of Madrid

Teresa Aldamis collaborates with several NGOs focused on HIV patients and migrants (COGAM, Asociación Triángulo, Fundación Triángulo, Apoyo Positivo).